Blog
Global Arteriovenous Fistula (AVF) Devices Market: Advancing the Future of Hemodialysis Access
The Global Arteriovenous Fistula (AVF) Devices Market was valued at approximately USD 379.6 million in 2025 and is projected to reach around USD 780.4 million by 2035, expanding at a CAGR of 7.4% during the forecast period.
The global healthcare industry is witnessing a major transformation in vascular access technologies as the burden of chronic kidney disease (CKD) and end-stage renal disease (ESRD) continues to rise worldwide. Among the most critical components of long-term dialysis treatment is reliable vascular access, and arteriovenous fistula (AVF) devices are rapidly emerging as a preferred solution for improving patient outcomes, reducing complications, and enhancing dialysis efficiency.
With millions of patients depending on hemodialysis every year, healthcare providers are increasingly prioritizing durable, infection-resistant, and minimally invasive AVF solutions. This growing focus is fueling strong momentum across the global arteriovenous fistula devices market.
Request a complimentary sample of the report here:
https://globaldatarouteanalytics.com/report/1421/arteriovenous-fistula-devices-market/download
Rising Burden of Kidney Disorders Driving Market Expansion
The sharp increase in CKD and ESRD cases is one of the strongest growth drivers for the AVF devices market. Sedentary lifestyles, diabetes, hypertension, obesity, and aging populations are significantly contributing to kidney-related complications globally.
As dialysis procedures become more common, hospitals and dialysis centers are under pressure to improve long-term vascular access management. AVF devices are preferred over central venous catheters due to their lower infection rates, better blood flow performance, and longer functional lifespan.
Healthcare systems across developed and emerging economies are now emphasizing early AVF placement and advanced fistula creation technologies to improve treatment efficiency and reduce hospitalization risks.
Technological Innovations Transforming AVF Procedures
The AVF devices market is experiencing rapid technological advancement, especially in minimally invasive and endovascular AVF creation procedures. Traditional surgical AVF creation remains widely used, but newer endovascular technologies are transforming patient experience and procedural efficiency.
Modern AVF systems now offer:
- Faster recovery time
- Reduced surgical trauma
- Lower infection risks
- Improved vessel preservation
- Better patient comfort
- Reduced hospital stays
The growing adoption of image-guided vascular procedures and catheter-based fistula creation techniques is also supporting market expansion globally.
In addition, manufacturers are investing heavily in vascular monitoring technologies and maturation enhancement devices to improve long-term AVF functionality and reduce access failure rates.
For any questions or clarifications, click here:
https://globaldatarouteanalytics.com/report/1421/arteriovenous-fistula-devices-market/inquiry
Growing Demand Across Dialysis Infrastructure
The expansion of dialysis infrastructure worldwide is creating significant opportunities for AVF device manufacturers. Governments and healthcare providers are increasing investments in renal care facilities, especially in emerging economies where dialysis access remains underdeveloped.
The growing number of outpatient dialysis centers and ambulatory surgical centers is further accelerating demand for advanced AVF technologies. Healthcare providers are increasingly adopting devices that improve workflow efficiency while minimizing patient complications.
Market Segmentation Analysis
By Product Type
- Surgical AVF Creation Devices
- Endovascular AVF (eAVF) Devices
- AVF Maturation and Accessory Devices
By Technique
- Conventional Surgical AVF Creation
- Minimally Invasive / Endovascular AVF Creation
By End User
- Hospitals
- Dialysis Centers
- Ambulatory Surgical Centers
Product Summary of Key Companies
Becton, Dickinson and Company (BD) – WavelinQ™ EndoAVF System Product Summary
- The WavelinQ™ EndoAVF System is a minimally invasive device designed for the endovascular creation of arteriovenous fistulas (AVFs) in patients with chronic kidney disease requiring long-term hemodialysis access.
- The system consists of two single-use 4F magnetic hydrophilic-coated catheters — an arterial catheter and a venous catheter — that enable accurate catheter alignment and controlled AVF creation using radiofrequency (RF) energy.
- The device supports AVF creation in additional anatomical locations, including radial artery-radial vein and ulnar artery-ulnar vein configurations, expanding treatment options beyond conventional surgical AVF procedures.
- The WavelinQ™ EndoAVF System is designed to improve procedural precision through magnetic catheter positioning, rotational alignment indicators, and compatibility with electrosurgical units (ESU) for efficient RF energy delivery.
Ellipsys™ Vascular Access System
- Single-catheter, nonsurgical system designed for the creation of an arteriovenous (AV) fistula for hemodialysis access.
- Enables minimally invasive endovascular AVF creation using thermal resistance energy between adjacent artery and vein.
- Designed to reduce surgical intervention and support faster vascular access procedures for chronic kidney disease patients requiring dialysis.
- Compatible with 0.014-inch guidewires and recommended for vessels with a minimum diameter of 2.0 mm.
- Includes reusable Ellipsys™ power controller and compatible EndoAVF™ access kit components for AVF procedures.
- Product status: Discontinued and available only for purchase by existing customers.
- Related AVF access support products include Fortrex™ HP PTA Balloon Catheter, IN.PACT™ AV Drug-Coated Balloon, and Nitrex™ Guidewire for AV access maintenance and intervention procedures.
MANTA® Vascular Closure Device
- Biomechanical vascular closure device specifically designed for large-bore femoral arterial access site closure following endovascular catheterization procedures.
- Available in 14 Fr. and 18 Fr. configurations for closure of femoral arterial access sites after the use of 10–20F devices or sheaths.
- Supports rapid hemostasis using collagen-based coagulation-inducing technology to promote vessel healing and reduce bleeding complications.
- Designed with a single-device deployment system that simplifies vascular closure procedures and improves procedural efficiency.
- Demonstrated strong technical success and safety outcomes in the SAFE MANTA IDE Clinical Trial for large-bore vascular access closure.
- Helps manage vascular access complications including bleeding, pseudoaneurysm formation, and arterio-venous fistula-related access management.
- Merit Medical offers a comprehensive Dialysis Access Portfolio supporting arteriovenous fistula (AVF) creation, graft placement, catheter insertion, declotting, and angioplasty procedures for hemodialysis patients.
- The company provides precision-engineered vascular access tools and accessories designed to establish and maintain reliable long-term dialysis access with reduced procedural complications.
- Merit’s AVF-related product solutions include hemodialysis balloons, renal accessories, and access maintenance technologies that support vascular intervention and dialysis access functionality.
- The portfolio is designed to optimize dialysis access procedures, improve insertion efficiency, and enhance long-term vascular access site performance across diverse patient populations.
- Merit Medical also supports clinicians through dialysis access clinical training programs, virtual education platforms, and dedicated clinical specialists for procedural guidance and troubleshooting assistance.
- Fresenius Medical Care provides a broad portfolio of in-center dialysis products, home dialysis systems, acute dialysis solutions, and vascular access support technologies for patients requiring long-term hemodialysis treatment.
- The company supports arteriovenous fistula (AVF)-based dialysis treatment through integrated dialysis care platforms, hemodialysis systems, and vascular access management solutions designed to improve treatment efficiency and patient outcomes.
- Fresenius Medical Care’s dialysis ecosystem includes products for home hemodialysis, peritoneal dialysis, and acute dialysis care, supporting reliable vascular access maintenance and long-term kidney disease management.
- The company continues advancing dialysis innovation through the rollout of its 5008X CAREsystems platform, focused on enhancing dialysis treatment performance, operational efficiency, and patient-centered renal care delivery.
- Fresenius Medical Care also provides extensive healthcare professional training, educational programs, and clinical support resources related to dialysis access management and chronic kidney disease treatment.
Access special deals and pricing here:
https://globaldatarouteanalytics.com/report/1421/arteriovenous-fistula-devices-market/discount
Competitive Landscape
The global AVF devices market is highly competitive, with leading medical device manufacturers focusing on technological innovation, strategic partnerships, product launches, and geographic expansion.
Key Players in the Global AVF Devices Market
- Becton, Dickinson and Company (BD)
- Medtronic plc
- Teleflex Incorporated
- Merit Medical Systems, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Getinge AB
- Terumo Corporation
- Cook Medical
- AngioDynamics, Inc.
- Avenu Medical, Inc.
- W. L. Gore & Associates, Inc.
- Boston Scientific Corporation
- Nipro Corporation
- Medikit Co., Ltd.
These companies are continuously investing in research and development activities aimed at improving vascular access outcomes and reducing AVF failure rates.
Future Outlook
The future of the arteriovenous fistula devices market looks highly promising as healthcare providers continue prioritizing safer and more durable dialysis access solutions.
The integration of minimally invasive vascular technologies, rising demand for outpatient procedures, expanding dialysis infrastructure, and growing awareness regarding kidney disease management are expected to drive long-term market growth globally.
As healthcare systems increasingly focus on reducing dialysis-related complications and improving patient quality of life, AVF devices will continue to play a vital role in the future of renal care.